Pharmacology of Cytostatic Drugs

作者: J. G. McVie , J. de Kraker

DOI: 10.1007/978-3-642-96889-1_3

关键词:

摘要: When planning to give a cytostatic drug patient, the broad assumptions are made that free active or drugs can be delivered target site, it tumour-cell membrane, nuclear DNA nucleotides; duration of exposure then regulated; and eventually cleared from site by metabolism excretion. The application such theory human situation is impossible without knowledge drug’s pharmacology. It now possible test sensitivity patient’s tumour variety in different doses schedules. To achieve same concentration child, however, absorption drug, distribution, liver clearance bile urine must considered. Drug disposition studies therefore become relevant optimizing treatment.

参考文章(12)
W Krivit, J Priest, C J Mirocha, S Pathre, D Doeden, N E Sladek, PLasma half-life and urinary excretion of cyclophosphamide in children. Cancer treatment reports. ,vol. 64, pp. 1061- 1066 ,(1980)
Joseph Aisner, P. H. Wiernik, S. Ostrow, N. R. Bachur, D. Hahn, S. Markus, A. LeRoy, M. J. Egorin, P. Chang, High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity Cancer treatment reports. ,vol. 65, pp. 73- 78 ,(1981)
Peter G. Steinherz, Laurel J. Steinherz, Ka Wah Chan, Counce Hancock, Anna Mondora, Michael Sorell, Denis R. Miller, Charlotte T. C. Tan, Phase II Study of 4′-(9-Acridinylamino)methanesulfon-m-anisidide (NSC 249992) in Children with Acute Leukemia and Lymphoma Cancer Research. ,vol. 42, pp. 1579- 1581 ,(1982)
M.H.N. Tattersall, M. Jarman, E.S. Newlands, L. Holyhead, R.A.V. Milstead, A. Weinberg, Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease European Journal of Cancer (1965). ,vol. 14, pp. 507- 513 ,(1978) , 10.1016/0014-2964(78)90253-0
J.F.B. Stuart, K.C. Claman, J. Watters, J. Paxton, B. Whiting, J.R. Lawrence, W.H. Steele, J.G. McVie, Bioavailability of methotrexate: implications for clinical use. Cancer Chemotherapy and Pharmacology. ,vol. 3, pp. 239- 241 ,(1979) , 10.1007/BF00254738
Irwin H. Krakoff, Esteban Cvitkovic, Violante Currie, Samual Yeh, Charles Lamonte, Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion Cancer. ,vol. 40, pp. 2027- 2037 ,(1977) , 10.1002/1097-0142(197711)40:5<2027::AID-CNCR2820400506>3.0.CO;2-A
EDWARD A NEUWELT, JAN T DIEHL, LONG H VU, SUELLEN A HILL, ANDREW J MICHAEL, EUGENE P FRENKEL, Monitoring of Methotrexate Delivery in Patients with Malignant Brain Tumors After Osmotic Blood-Brain Barrier Disruption Annals of Internal Medicine. ,vol. 94, pp. 449- 454 ,(1981) , 10.7326/0003-4819-94-4-449
A Rossi, G Bonadonna, P Valagussa, U Veronesi, Multimodal treatment in operable breast cancer: five-year results of the CMF programme. BMJ. ,vol. 282, pp. 1427- 1431 ,(1981) , 10.1136/BMJ.282.6274.1427
William G. Woods, Maura O'Leary, Mark E. Nesbit, Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia The Journal of Pediatrics. ,vol. 98, pp. 642- 645 ,(1981) , 10.1016/S0022-3476(81)80785-8
Emil Frei, George P. Canellos, Dose: A Critical Factor in Cancer Chemotherapy The American Journal of Medicine. ,vol. 69, pp. 585- 594 ,(1980) , 10.1016/0002-9343(80)90472-6